NCT01941004View on ClinicalTrials.gov

Safety and Efficacy of Fingolimod in MS Patients in China

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Multiple Sclerosis (Relapsing Remitting)
Interventions
DRUG

fingolimod

Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

DRUG

Placebo (6mos) + open label fingolimod (6 mos)

Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY